Subject Diagnostic Imaging

A Pragmatic Trial of Tomosynthesis vs Digital Mammography for Breast Cancer Screening (TMIST)

The Tomosynthesis Mammographic Imaging Screening Trial (TMIST or study EA1151) is a randomized breast cancer screening study. The ECOG-ACRIN Cancer Research Group opened the trial on July 6, 2017, and is currently enrolling about 165,000 women who are planning to have regular mammograms. TMIST is very important to the future of breast cancer screening because it will give us knowledge about how to move beyond our current “one size fits all” approach, where we screen most women the same way based on age-specific guidelines.

Analysis of Adverse Event Data to Optimize Strategies for the Longitudinal Assessment of Tolerability in the Context of Evolving Cancer Treatment Paradigms (EVOLV)

EVOLV proposes to deliver sophisticated and standardized methods for assessing, monitoring, analyzing, and reporting adverse events (AEs) experienced by individuals undergoing cancer treatment.

Advancing Quantitative Cancer Imaging in Clinical Trials (QIN)

The evolution in our understanding of cancer requires an evolution in the design and implementation of clinical trials, and the quantitative imaging used to assess therapeutic efficacy. This was noted in the Institute of Medicine's influential report A National Cancer Clinical Trials System for the 21st Century, which stated that 'the current structure and processes of the entire clinical trials system need to be redesigned to improve value by reducing redundancy and improving the effectiveness and efficiency of trials'.